Halozyme Reports 2025 Record Revenue and 2026 Guidance

Halozyme Therapeutics reported full-year 2025 results with record total revenue of $1.397 billion, up 38% year over year. Royalty revenue reached a record $868 million, up 52% year over year, driven by ENHANZE-enabled products including DARZALEX SC, Phesgo, and VYVGART Hytrulo.

The company reiterated 2026 financial guidance, projecting total revenue of $1.710 to $1.810 billion (22% to 30% growth) and adjusted EBITDA of $1.125 to $1.205 billion (71% to 83% growth). Halozyme also reiterated non-GAAP diluted EPS of $7.75 to $8.25.

Halozyme said it completed acquisitions of Elektrofi and Surf Bio in 2025 to expand its drug delivery technology portfolio, and it referenced additional ENHANZE collaboration and licensing agreements during the year.